All News
Growing Physician Enthusiasm for AI in Healthcare
The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.
Read Article
The Cartel is Coming for Rheumatology
"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.
Read Article
Combination biologics in PsA: are we there yet?
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.
Read Article
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
8 fold risk of incident ILD in #RA pts. Data from Korean National Health Insurance, 52,325 RA pts & 261,625 controls & 4.4 yrs F/U - ILD in 3.7% of RA vs 0.5% controls (adjHR 7.84); higher in seropositive RA (aHR= 9) vs seronegative RA (aHR=4.8) https://t.co/iIoZOwFYEN https://t.co/HBzSg9KrpZ
Dr. John Cush RheumNow ( View Tweet)
Survey on Corticosteroid (CS) use in PFAPA syndrome included 144 MDs (67% pedi-Rheums); 92% use CS in PFAPA flares. 42% expected a response w/in 12 hrs. 31% use CS ‘routinely. Med literature cites Prednisone as most preferred CS (48%). Response to CS ~ 95% https://t.co/V1wkhNaNAP https://t.co/YILAlKrUcQ
Dr. John Cush RheumNow ( View Tweet)
Lupus flares after ESRD? Metanalysis of 34 studies (29 on HD/PD; 5 post transplant/KT) - extra-renal flares seen in 36% of ESRD pts & were significantly higher w/ PD/HD vs KT (OR: 4.36; 1.66-11.47, p=0.0028). Recurrence of LN after KT was 3.4% https://t.co/tXlyxsfvXd https://t.co/tzsMCeRkz4
Dr. John Cush RheumNow ( View Tweet)
EGPA in 2025
Eosinophilic Granulomatosis with Polyangiitis (EGPA), the artist formerly known as Churg-Strauss syndrome, remains somewhat of a rogue agent among the vasculitides.
https://t.co/4ofjQRYsMH https://t.co/PoVhaQ9QiZ
Links:
Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011
80% #hydradenitis suppurativa pts are smokers or former smokers, smoking can predate #HS by 4-5 years. Other associations: DM-2, Spa, obesity, SAPHO, PCOS eval for SCC (squ. cell CA) #RNL2025 https://t.co/XHrFseiAMK
Dr. John Cush RheumNow ( View Tweet)
Janet Pope @Janetbirdope
#Disease #activity in #axSpA
#ASDAS - a crude measure of activity in
#ankylosing #spondylitis
Is related to #radiographic #progression
👇
⬆️ CRP May be more predictive
#ClinicalPearl #RNL2025 https://t.co/34wrMuz9mO
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
Active Morphea: - MTX +/- steroids. If not effective, MMF/RTX/ABA - Topicals for circumscribed - Phototherapy Most pts achieve remission in active in 1 year Inactive morphea - Can address with PT, pain rx, psychological support, plastic surgery fat… https://t.co/OMGt8feO0z https://t.co/yWAgY2Z4Ng
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
How do you know if Morphea is active? -Erythema -Peripheral induration -New lesions in the past few month Non-active damage? - Dermal atrophy -SQ atrophy -Hyperpigmentation -Skin thickness center #RNL2025
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
#RNL2025 Treatment of sclerosing skin conditions: Active inflammation? Sclerotic? Atrophic? Target based on activity, depth of involvement and other disease involvement
Dr. John Cush RheumNow ( View Tweet)
MD Survey: Who should manage patients with hidradentis supprativa?
Dr. John Cush RheumNow ( View Tweet)
Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025
Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA
FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/5Tb8on21E0 https://t.co/BLu6Zaejj5
Links:
Dr. John Cush RheumNow ( View Tweet)
Janet Pope @Janetbirdope
#ClinicalPearl Insights into #fibrosing #skin conditions Inflammatory Fibrotic Atrophy We treat the #inflammation but need to determine if lesions are active or not Bx May not discern #dx Heidi Jacobe #RNL2025 https://t.co/dG1k4fm4aO https://t.co/5TowCCDiTt
Links:
Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011
@drcharitydean on emerging public health threats including H5N1 & communicable dz. We need to be monitoring for human to human disease transmissions. There is a high level of concern by large business as they recognize this will affect the supply chain.… https://t.co/T3TZ7LtHQi https://t.co/Ar85A0EcW4
Dr. John Cush RheumNow ( View Tweet)
That's not my problem - or is it? Multimorbidity in RA
RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment.
https://t.co/B7WUiysNSE https://t.co/nczmoIBfOb
Dr. John Cush RheumNow ( View Tweet)
The POWER of #plaquenil
#Hydroxychloroquine works in #rheumatic #diseases by
Old answer
👇
Alters liposomal membranes 🤷♀️
NEW ANSWER
Inhibits TLR signalling 🔥
#RNL2025 Mary *Peggy Crow #SLE #systemic #lupus #erythematosus https://t.co/j2YQjVIpcy
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
B England
75% of RA pts have multi-morbidity
Pts develop multi-morbidity BEFORE the onset of RA
Should we have different goals: Prioritize LDA over remission in pts w multimorbidity
Collaborate w PCP: one size doesn't fit all, do something better than… https://t.co/RIe7BhSgvJ https://t.co/4dVdR088XF
Dr. John Cush RheumNow ( View Tweet)